Abstract Title:

Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease.

Abstract Source:

Med J Aust. 2007 Jan 15 ;186(2):91-4. PMID: 17223772

Abstract Author(s):

Tim Walker, Joe McCaffery, Chris Steinfort

Article Affiliation:

Geelong Hospital, Geelong, Victoria, Australia. [email protected]

Abstract:

Over a 3-year period, seven patients who were taking HMG-CoA reductase inhibitors (statins) presented to our respiratory service with interstitial pneumonitis. Clinical course varied, with the condition responding to prednisolone treatment and cessation of statins in three patients, and progressing slowly despite this management in another three, while one patient died of associated cardiac disease. While a causative role cannot be confirmed, clinicians should be aware of the possible association.

Study Type : Review

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.